St Tab 7.5 mg
Sodium Thiosulfate
Category: Tablet
Manufacturer: Techno Drugs Ltd., Satipara, Narshingdi
Techno Drugs Ltd., Satipara, Narshingdi
Allopathic
MFG. Licence No. Biological
211
MFG. Licence No. Non-Biological
446
Address
Satipara, Narshingdi
Medicine Selling service is not available yet.
Related Medicines
Calcium urolithiasis, Cyanide poisoning, Secondary Preventive Treatment for Calciphylaxis in Dialysis Patients
Oedematous sodium-retaining conditions.
Antidote preparations
Sodium thiosulfate acts as an antidote in the treatment of cyanide poisoning. It acts as a sulphur-donating substrate for the enzyme rhodanese, thus speeding up the conversion of cyanide to thiocyanide, which is relatively non toxic. It is often used in combination with sodium nitrite but may be used alone in less severe poisoning.
Adult Dose:
Oral
A 2 M (molar) solution can be prepared with 74.4 g in 150 mL free water; 2.6 g can be given orally daily or 3 times a week.
Dose is limited by diarrhea.
Decreases toxicity of cisplatin through rapid chemical inactivation of its platinum component.
Oedematous sodium-retaining conditions.
Osmotic disturbances. Oral: catharsis (at high doses).
Pregnancy Category C. There are no adequate and well controlled studies in pregnant women. Sodium Thiosulfate Injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether sodium thiosulfate is excreted in human milk. Because Sodium Thiosulfate Injection may be administered in life-threatening situations, breast-feeding is not a contraindication to its use. Because many drugs are excreted in human milk, caution should be exercised following Sodium Thiosulfate Injection administration to a nursing woman. There are no data to determine when breastfeeding may be safely restarted following administration of sodium thiosulfate.
Precaution:
May irritate eyes, skin and respiratory tract.
There is limited information about the effects of large doses of sodium thiosulfate in humans. Oral administration of 3 g sodium thiosulfate per day for 1-2 weeks in humans resulted in reductions in room air arterial oxygen saturation to as low as 75%, which was due to a rightward shift in the oxygen hemoglobin dissociation curve. The subjects returned to baseline oxygen saturations 1 week after discontinuation of sodium thiosulfate. A single intravenous administration of 20 mL of 10% sodium thiosulfate reportedly did not change oxygen saturations.
Store at controlled room temperature between 20°C and 25°C. Protect from direct light. Do not freeze.
Antidote preparations
Thiosulfate is sulfur donor utilized by rhodenase to convert cyanide to less toxic thiocyanate.
Cisplatin toxicity: Na-thiosulfate combines w/ cisplatin to form a complex nontoxic to both normal/cancerous cells. Increases solubility of calcium.
Pregnancy Category C. There are no adequate and well controlled studies in pregnant women. Sodium Thiosulfate Injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether sodium thiosulfate is excreted in human milk. Because Sodium Thiosulfate Injection may be administered in life-threatening situations, breast-feeding is not a contraindication to its use. Because many drugs are excreted in human milk, caution should be exercised following Sodium Thiosulfate Injection administration to a nursing woman. There are no data to determine when breastfeeding may be safely restarted following administration of sodium thiosulfate.
Samm Care